Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Technology / Ensysce Biosciences Initiates Opioid Study
Tech clinical trial

Ensysce Biosciences Initiates Opioid Study

Analysis based on 7 articles · First reported Jun 26, 2026 · Last updated Jun 26, 2026

Sentiment
60
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The initiation of the final stage of the PF614-MPAR-102 clinical study by Altor BioScience is a positive development for the pharmaceutical industry, particularly for companies focused on pain management and addiction. Successful completion and approval of this drug could significantly impact the market for opioid therapeutics by introducing a safer alternative, potentially reducing the societal and economic burden of opioid overdose.

pharmaceutical biotechnology
Event Summary

Altor BioScience announced the initiation of the final stage of its PF614-MPAR-102 clinical study on June 26, 2026. This study evaluates its novel MPAR (Multi-Pill Abuse Resistance) overdose-protection technology, an opioid engineered to protect against oral overdose. The drug, which received Breakthrough Therapy designation from the United States — Food and Drug Administration, aims to provide active protection by restricting additional opioid release at excessive doses. The United States — National Institutes of Health is supporting Part 3 of this study. Lynn Kirkpatrick, CEO of Altor BioScience, highlighted the potential of PF614-MPAR to establish a new standard for opioid safety and address the opioid crisis in the United States.

Entities Involved
priv
Altor BioScience
Altor BioScience announced the initiation of the final stage of its PF614-MPAR-102 clinical study, which is a significant step in the development of its novel opioid overdose-protection technology. This could lead to a new standard for opioid safety and expand its market reach.
Importance 100.0 Sentiment 70.0
per
Lynn Kirkpatrick
Lynn Kirkpatrick, as CEO of Altor BioScience, provided key statements regarding the significance of the PF614-MPAR technology in addressing the opioid crisis and establishing a new standard for opioid safety.
Importance 80.0 Sentiment 60.0
govactor
United States — National Institutes of Health
The United States — National Institutes of Health is supporting Part 3 of the PF614-MPAR-102 study, indicating government interest and potential validation for Altor BioScience' technology.
Importance 40.0 Sentiment 50.0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration granted Breakthrough Therapy designation to PF614-MPAR, which highlights the potential importance of Altor BioScience' drug.
Importance 40.0 Sentiment 50.0
cnt
United States
The United States is the primary market for Altor BioScience' drug, and the opioid crisis within the United States is the problem that Altor BioScience is trying to solve.
Importance 30.0 Sentiment 50.0
Relationships
United States — National Institutes of Health related ↔ United States — Food and Drug Administration
United States — National Institutes of Health related ↔ United States
United States — Food and Drug Administration related ↔ United States
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.